CSF-G Latest Research Articles & Clinical Trials & Targets & Indications

What is CSF-G?

CSF-G is a recombinant proteins developed by Dong-A ST. It is approved for therapeutic indications via injectable (others) or subcutaneous injection.

Drug Profile

Company	Dong-A ST
Drug Class	Recombinant Proteins
Molecular Target	CSF3R
Route	Injectable (Others), Subcutaneous Injection
Status	Approved

Sources: ClinicalTrials.gov, Dong-A ST

Mechanism of Action

Molecular Targets

CSF-G acts on 1 molecular target:

CSF3R

colony stimulating factor 3 receptor (CD114, GCSFR)

Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Clinical Trials

There are currently 695 clinical trials registered

Trial ID	Phase	Title	Status
NCT06059391	Phase 2	Placebo-Controlled and Randomized Phase 2 Trial of CMV-MVA Triplex Vaccination in HLA-Matched Relate	● Recruiting
NCT01050036	NA	Phase 2 Study of Autologous Hematopoietic Cell Transplantation for Core-binding Factor Positive Acut	Completed
NCT01186224	NA	A Comparison of Plerixafor/G-CSF with Chemotherapy/G-CSF for Stem Cell Mobilisation	Completed
NCT04446130	Phase 3	A Phase 3, Open Label, Single Arm, Multi-Center Study to Evaluate the Efficacy and Safety of Decitab	Unknown
NCT04519424	Phase 2	A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate CSL324 in Cor	Withdrawn
NCT04411212	Phase 2	Granulocyte Colony-stimulating Factor and Platelet-rich Plasma Group in Patients With Recurrent Impl	Unknown

+691 more trials available with a free account

Sign up free to view all clinical trials →

Analyze Full Trial DataNoah can compare efficacy across trials and generate reports.

Therapeutic Indications

CSF-G is developed for 1 unique indication across 1 therapeutic area.

Therapeutic Area	Condition	Phase
Blood and lymphatic system disorders	Neutropenia	✓ Approved

CSF-G